サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：結核治療市場- 世界の産業規模、シェア、動向、機会、および予測、2018-2028年
市場調査レポート
商品コード
1326475

結核治療市場- 世界の産業規模、シェア、動向、機会、および予測、2018-2028年

Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Disease Type, By Therapy, By Route of Administration, By Dosage Form, By Distribution Channel, By Region and Competition
出版日: | 発行: TechSci Research | ページ情報: 英文 113 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

結核治療市場- 世界の産業規模、シェア、動向、機会、および予測、2018-2028年
出版日: 2023年08月01日
発行: TechSci Research
ページ情報: 英文 113 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

結核治療の世界市場は、結核の蔓延と闘い、患者の予後を改善するための新たな治療法を見出す必要性が高まっていることから、予測期間中に目覚ましい成長が見込まれています。

結核は、結核菌によって引き起こされる感染性の高い致死的な疾患です。結核は主に肺を侵すが、脳、腎臓、脊椎など、身体の他の部位を侵すこともあります。世界保健機関（WHO）によると、結核は世界の死因トップ10のひとつであり、2019年には1,000万人がこの病気にかかると推定されています。このような高い罹患率を背景に、結核治療に対する需要は今後も増加すると予想され、予測期間中の世界の結核治療市場の成長を牽引します。

薬剤耐性の増加

結核は、急速に変異する可能性のある細菌によって引き起こされ、治療が困難な薬剤耐性株につながります。多剤耐性結核（MDR-TB）と広範囲薬剤耐性結核（XDR-TB）は、世界保健に重大な課題をもたらす薬剤耐性結核の2つの形態です。薬剤耐性結核菌の出現により、これらの治療困難な結核菌を効果的に治療できる新規結核治療の需要が高まっています。その結果、結核に関連する薬剤耐性の問題に対処できる新規治療薬に対する需要が増加し、今後数年間の世界の結核治療市場の成長を促進すると予想されます。過去10年間で、ベダキリン、デラマニド、プレトマニドなど、いくつかの新しい結核治療が開発されました。ベダキリンは、多剤耐性（MDR）結核や広範囲薬剤耐性（XDR）結核を含む薬剤耐性結核に有効であることが示されている新規薬剤です。デラマニドも、特に他の結核治療と併用した場合に、薬剤耐性結核に有効であることが示されています。プレトマニドは3剤の中で最も新しい薬剤で、広範囲薬剤耐性結核の治療薬として承認されています。

結核診断の進歩

診断ツールの進歩も結核治療を改善してきました。その一例が、わずか2時間で結核と薬剤耐性を検出できる迅速分子診断検査であるXpert MTB/RIFの使用です。もう一つの診断ツールは、90分以内に結核と薬剤耐性を検出できるGeneXpert Omniです。これらのツールは、臨床医がより正確な診断を下し、患者に最も適切な治療レジメンを選択するのに役立ちます。結核の診断法の開拓は、効果的な治療法の開発にもつながっており、その結果、今後数年間の世界の結核治療市場の成長に新たな展望が開かれることになります。

併用療法の使用

さまざまな慢性疾患や感染症の治療における併用療法の使用は年々増加しており、新規治療薬の成長と開発に新たな機会がもたらされています。結核の治療においても、併用療法の使用はますます一般的になってきています。併用療法は結核の治療に複数の薬剤を使用するもので、治療成績を向上させ、薬剤耐性のリスクを軽減することができます。併用療法の一例として、MDR-TBの治療におけるベダキリンとデラマニドの使用が挙げられます。BPaMZレジメンと呼ばれる別の併用療法では、薬剤感受性結核の治療にベダキリン、プレトマニド、モキシフロキサシン、ピラジナミドを使用しています。結核治療における併用療法の使用は、今後数年間、世界の結核治療市場の成長を牽引すると予想されます。

研究開発活動の活発化

近年、結核の研究開発に再び注目が集まっています。これにより、結核患者の治療成績を改善する可能性のある新薬や治療法が発見されています。結核の研究開発への注目の高まりは、新しく革新的な結核治療への需要も高めています。clinicaltrials.govによると、結核と闘うための治療法を開発するためのさまざまな段階の研究が世界中で約1092件行われています。

さらに、より短いレジメンで効果的な治療法を見つけるための研究も進められています。従来、結核の治療には抗生物質の長期投与が必要で、その期間は2年に及ぶこともあっています。しかし、最近の調査では、より短い治療レジメンでも同様の効果があることが示されています。その一例がBPaLレジメンで、これは薬剤耐性結核の治療にベダキリン、プレトマニド、リネゾリドを使用するものです。このレジメンは、わずか6ヵ月で結核を治療する効果があることが示されています。このことは、今後数年間、世界の結核治療市場の成長を支えるものと期待されます。

このような新薬やレジメンに加えて、研究者たちは既存の薬剤を結核治療に再利用する可能性も模索しています。例えば、2020年にScience誌に発表された研究では、現在腸内感染症の治療に使用されているニクロサミドという薬剤が、実験室での実験で結核菌の死滅に有望な結果を示したことが明らかになっています。研究者らは現在、ヒトでの結核治療におけるニクロサミドの有効性を検証する臨床試験を計画しています。これにより、今後数年間、世界の結核治療市場の成長に新たな展望が開けると期待されています。

HIVの有病率の増加

HIVは、体があらゆる種類の感染症と闘うのを助ける細胞を攻撃するウイルスであり、HIVに感染した患者は他の病気や感染症にかかりやすくなります。WHOによると、2021年現在、HIV感染者は世界で約3,840万人に上ります。HIV感染者は免疫力が低下しているため、結核を発症するリスクが非常に高いです。WHOによると、結核患者の約8％がHIV陽性者です。結核とHIVの重複感染が多いことから、両方の病気を効果的に治療できる結核治療の需要が高まっており、世界の結核治療市場の成長を支えています。

最近の動向

  • 2019年、大塚製薬株式会社は、広範囲薬剤耐性結核の治療薬として、結核新薬プレトマニドの承認を米国食品医薬品局（FDA）から取得しました。
  • グラクソ・スミスクライン（GSK）は、薬剤耐性結核に有効な薬剤の開発に重点を置いた結核治療開発プログラムを持っています。GSKは現在、GSK3036656と呼ばれる薬剤を臨床試験中で、初期の研究で有望な結果を示しています。
  • 2019年、米国食品医薬品局（FDA）はプレトマニドという新薬を承認しました。プレトマニドは、ベダキリンとリネゾリドも含むBPaLと呼ばれる3剤併用レジメンの一部であり、高度薬剤耐性型結核の治療に高い効果があることが示されています。南アフリカで実施された第III相試験では、BPaLレジメンは、主要な結核治療のうち少なくとも4剤に耐性を示す広範囲薬剤耐性結核患者の90％を治癒させました。また、BPaLレジメンは、薬剤耐性結核に対する従来の標準治療よりも期間が短く、最長2年かかるところをわずか6ヵ月で済ませることができます。

利用可能なカスタマイズ

TechSci Researchは、所定の市場データを使用して、企業固有のニーズに応じたカスタマイズを提供します。レポートでは以下のカスタマイズが可能です：

企業情報

  • 追加市場プレイヤー（最大5社）の詳細分析とプロファイリング

目次

第1章 概要

  • 市場の定義
  • 市場の範囲
    • 対象市場
    • 調査対象年
    • 主要市場セグメンテーション

第2章 調査手法

  • 調査目的
  • ベースライン調査手法
  • 主要産業パートナー
  • 主要協会と二次情報源
  • 予測手法
  • データの三角測量と検証
  • 仮定と限界

第3章 エグゼクティブサマリー

  • 市場概要
  • 主要市場セグメンテーションの概要
  • 主要市場プレーヤーの概要
  • 主要地域/国の概要
  • 市場促進要因・課題・動向の概要

第4章 顧客の声

第5章 結核治療の世界市場展望

  • 市場規模・予測
    • 金額ベース
  • 市場シェアと予測
    • 疾患タイプ別（活動性結核、潜在性結核）
    • 治療法別（ファーストライン治療、セカンドライン治療）
    • 投与経路別（経口、非経口、その他）
    • 剤形別（錠剤、カプセル剤、注射剤、その他）
    • 流通チャネル別（病院、小売薬局、オンライン薬局）
    • 地域別
    • 企業別（2022年）
  • 製品マップ
    • 疾患タイプ別
    • 治療法別
    • 投与経路別
    • 剤形別
    • 販売チャネル別
    • 地域別

第6章 北米の結核治療市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 疾患タイプ別
    • 治療法別
    • 投与経路別
    • 剤形別
    • 流通チャネル別
    • 国別
  • 北米国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の結核治療市場展望

  • 市場規模・予測
    • 金額ベース
  • 市場シェアと予測
    • 疾患タイプ別
    • 治療法別
    • 投与経路別
    • 剤形別
    • 流通チャネル別
    • 国別
  • 欧州国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋の結核治療市場展望

  • 市場規模および予測
    • 金額ベース
  • 市場シェアと予測
    • 疾患タイプ別
    • 治療法別
    • 投与経路別
    • 剤形別
    • 流通チャネル別
    • 国別
  • アジア太平洋地域国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第9章 南米の結核治療市場の展望

  • 市場規模および予測
    • 金額ベース
  • 市場シェアと予測
    • 疾患タイプ別
    • 治療法別
    • 投与経路別
    • 剤形別
    • 流通チャネル別
    • 国別
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの結核治療市場の展望

  • 市場規模・予測
    • 金額ベース
  • 市場シェアと予測
    • 疾患タイプ別
    • 治療法別
    • 投与経路別
    • 剤形別
    • 流通チャネル別
    • 国別
  • MEA：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の展開
  • 合併・買収
  • 製品発表

第13章 世界の結核治療市場SWOT分析

第14章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第15章 競合情勢

  • Business Overview
  • Service Offerings
  • Recent Developments
  • Key Personnel
  • SWOT Analysis
    • AstraZeneca
    • Johnson & Johnson
    • Eli Lilly And Company
    • Mylan N.V.
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi SA
    • Novartis AG
    • Sun Pharmaceutical Industries Ltd.
    • Pfizer Inc.

第16章 戦略的提言

目次
Product Code: 14842

Global Tuberculosis Therapeutics Market is expected to grow at an impressive rate during the forecast period on account of the growing need to find new therapeutic solutions to combat the spread of tuberculosis and improve patient outcomes. Tuberculosis (TB) is a highly infectious and potentially fatal disease caused by the bacteria Mycobacterium tuberculosis. It primarily affects the lungs but can also target other parts of the body, including the brain, kidneys, and spine. According to the World Health Organization (WHO), TB is one of the top 10 causes of death worldwide, with an estimated 10 million people falling ill with the disease in 2019. With such a high incidence rate, the demand for tuberculosis therapeutics is expected to continue to rise, thereby driving the growth of global tuberculosis therapeutics market during the forecast period.

Tuberculosis is a global health issue that affects people of all ages and from all walks of life. Despite the availability of effective treatments, the disease continues to be a major public health concern, particularly in low and middle-income countries. According to the WHO, over 90% of TB cases occur in developing countries, where access to proper healthcare and diagnostic tools is limited. As a result, there is an urgent need for effective, affordable, and accessible TB therapeutics to address the global burden of the disease. This, in turn, is expected to drive the growth of global tuberculosis therapeutics market in the coming years.

Additionally, global population is aging, and older adults are more susceptible to TB due to age-related declines in immune function. As the population continues to age, the demand for TB therapeutics that are safe and effective in older adults is expected to increase, thereby driving the growth of global tuberculosis therapeutics market.

Increasing Instances of Drug Resistance

Tuberculosis is caused by a bacterium that can mutate rapidly, leading to drug-resistant strains that are difficult to treat. Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) are two forms of drug-resistant TB that pose a significant challenge to global health. The emergence of drug-resistant strains of TB has increased the demand for novel TB therapeutics that can effectively treat these difficult-to-treat strains. This, in turn, is expected to increase the demand for novel therapeutics that can address the issue of drug resistance related to tuberculosis, thereby fuelling the growth of global tuberculosis therapeutics market in the coming years. In the past decade, several new TB drugs have been developed, including bedaquiline, delamanid, and pretomanid. Bedaquiline is a novel drug that has been shown to be effective against drug-resistant TB, including multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB. Delamanid has also been shown to be effective against drug-resistant TB, particularly when used in combination with other TB drugs. Pretomanid, the newest of the three drugs, has been approved for the treatment of extensively drug-resistant TB.

Advancements in Tuberculosis Diagnostics

Advances in diagnostic tools have also improved the treatment of TB. One example is the use of Xpert MTB/RIF, a rapid molecular diagnostic test that can detect TB and drug resistance in just two hours. Another diagnostic tool is the GeneXpert Omni, which can detect TB and drug resistance in less than 90 minutes. These tools can help clinicians make more accurate diagnoses and choose the most appropriate treatment regimen for their patients. The development in diagnostic methods for tuberculosis is leading to the development of effective therapeutic solutions as well, thereby opening new prospects for the growth of global tuberculosis therapeutics market in the coming years.

Use of Combination Therapies

The use of combination therapies in the treatment of various chronic and infectious diseases has increased over the years, significantly opening new opportunities for the growth and development of novel therapeutics. The use of combination therapies is becoming increasingly common in the treatment of TB. Combination therapies involve the use of multiple drugs to treat TB, which can improve treatment outcomes and reduce the risk of drug resistance. One example of combination therapy is the use of bedaquiline and delamanid in the treatment of MDR-TB. Another combination therapy, called the BPaMZ regimen, uses the drugs bedaquiline, pretomanid, moxifloxacin, and pyrazinamide to treat drug-sensitive TB. The use of combination therapies in the treatment of tuberculosis is expected to drive the growth of global tuberculosis therapeutics market in the coming years.

Increased Research and Development Activities

In recent years, there has been a renewed focus on TB research and development. This has led to the discovery of new drugs and therapies that have the potential to improve treatment outcomes for patients with TB. The increased focus on TB research and development has also increased the demand for new and innovative TB therapeutics. According to clinicaltrials.gov, there are around 1,092 studies in different phases of development across the globe for developing a treatment for combating tuberculosis.

Additionally, studies are going on to find effective treatments with shorter regimens. Traditionally, TB treatment has involved a long course of antibiotics that can last for up to two years. However, recent research has shown that shorter treatment regimens may be just as effective. One example is the use of the BPaL regimen, which uses the drugs bedaquiline, pretomanid, and linezolid to treat drug-resistant TB. This regimen has been shown to be effective in treating TB in as little as six months. This, in turn, is expected to support the growth of global tuberculosis therapeutics market in the coming years.

In addition to these new drugs and regimens, researchers are also exploring the potential of repurposing existing drugs for the treatment of TB. For example, a study published in the journal Science in 2020 found that a drug called niclosamide, which is currently used to treat intestinal infections, showed promising results in killing Mycobacterium tuberculosis in laboratory experiments. The researchers are now planning to conduct clinical trials to test niclosamide's effectiveness in treating TB in humans. This is further expected to open new prospects for the growth of global tuberculosis therapeutics market in the coming years.

Growing Prevalence of HIV

HIV is a virus that attacks cells that help the body fight any kind of infection, making the patient suffering from HIV more vulnerable to other diseases and infections. According to WHO, as of 2021, there are around 38.4 million people living with HIV worldwide. People who are infected with HIV are at a much higher risk of developing TB due to their weakened immune systems. According to the WHO, around 8% of all TB cases are HIV-positive. The high prevalence of TB/HIV co-infection has increased the demand for TB therapeutics that can effectively treat both diseases, thereby supporting the growth of global tuberculosis therapeutics market.

Market Segmentation

Global Tuberculosis Therapeutics Market can be segmented by disease type, therapy, route of administration, dosage form, distribution channel, and by region. Based on disease type, global tuberculosis therapeutics market can be split into active tuberculosis and latent tuberculosis. By therapy, the global tuberculosis therapeutics market can be divided into first-line therapy and second-line therapy. Based on the route of administration, global tuberculosis therapeutics can be categorized into oral, parenteral, and others. By dosage form, the global tuberculosis therapeutics market can be segmented into tablets, capsules, injections, and others. In terms of distribution channels, the global tuberculosis therapeutics market can be grouped into hospital pharmacy, retail pharmacy, and online pharmacy. Regionally, the global tuberculosis therapeutics market can be segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa.

Market Players

AstraZeneca, Plc., Johnson & Johnson, Eli Lilly And Company, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi SA, Novartis AG, Sun Pharmaceutical Industries Ltd., Pfizer Inc., among others, are some of the leading players operating in the global Tuberculosis Therapeutics market.

Recent Developments

  • In 2019, Otsuka Pharmaceutical Co., Ltd. received approval from the U.S. Food and Drug Administration (FDA) for a new TB drug, Pretomanid, for the treatment of extensively drug-resistant TB.
  • GlaxoSmithKline (GSK), which has a TB drug development program focused on developing drugs that are effective against drug-resistant TB. GSK is currently testing a drug called GSK3036656 in clinical trials, which has shown promise in early studies.
  • In 2019, the US Food and Drug Administration (FDA) approved a new drug called pretomanid. Pretomanid is part of a three-drug regimen called BPaL, which also includes bedaquiline and linezolid, which has been shown to be highly effective in treating highly drug-resistant forms of TB. In a phase III trial conducted in South Africa, the BPaL regimen cured 90% of patients with extensively drug-resistant TB, a form of TB that is resistant to at least four of the main TB drugs. The BPaL regimen is also shorter than the previous standard of care for drug-resistant TB, taking just six months instead of up to two years.

Report Scope:

In this report, Global Tuberculosis Therapeutics Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Tuberculosis Therapeutics Market, By Disease Type:

  • Active Tuberculosis
  • Latent Tuberculosis

Tuberculosis Therapeutics Market, By Therapy:

  • First Line Therapy
  • Second Line Therapy

Tuberculosis Therapeutics Market, By Route of Administration:

  • Oral
  • Parenteral
  • Others

Tuberculosis Therapeutics Market, By Therapy:

  • First Line Therapy
  • Second Line Therapy

Tuberculosis Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Tuberculosis Therapeutics Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Tuberculosis Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease Type (Active Tuberculosis, Latent Tuberculosis)
    • 5.2.2. By Therapy (First Line Therapy, Second Line Therapy)
    • 5.2.3. By Route of Administration (Oral, Parenteral, Others)
    • 5.2.4. By Dosage Form (Tablets, Capsules, Injection, Others)
    • 5.2.5. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 5.2.6. By Region
    • 5.2.7. By Company (2022)
  • 5.3. Product Map
    • 5.3.1. By Disease Type
    • 5.3.2. By Therapy
    • 5.3.3. By Route of Administration
    • 5.3.4. By Dosage Form
    • 5.3.5. By Distribution Channel
    • 5.3.6. By Region

6. North America Tuberculosis Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Type
    • 6.2.2. By Therapy
    • 6.2.3. By Route of Administration
    • 6.2.4. By Dosage Form
    • 6.2.5. By Distribution Channel
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Tuberculosis Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease Type
        • 6.3.1.2.2. By Therapy
        • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.4. By Dosage Form
        • 6.3.1.2.5. By Distribution Channel
    • 6.3.2. Canada Tuberculosis Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease Type
        • 6.3.2.2.2. By Therapy
        • 6.3.2.2.3. By Route of Administration
        • 6.3.2.2.4. By Dosage Form
        • 6.3.2.2.5. By Distribution Channel
    • 6.3.3. Mexico Tuberculosis Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease Type
        • 6.3.3.2.2. By Therapy
        • 6.3.3.2.3. By Route of Administration
        • 6.3.3.2.4. By Dosage Form
        • 6.3.3.2.5. By Distribution Channel

7. Europe Tuberculosis Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Type
    • 7.2.2. By Therapy
    • 7.2.3. By Route of Administration
    • 7.2.4. By Dosage Form
    • 7.2.5. By Distribution Channel
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Tuberculosis Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Type
        • 7.3.1.2.2. By Therapy
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By Dosage Form
        • 7.3.1.2.5. By Distribution Channel
    • 7.3.2. Germany Tuberculosis Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Type
        • 7.3.2.2.2. By Therapy
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By Dosage Form
        • 7.3.2.2.5. By Distribution Channel
    • 7.3.3. United Kingdom Tuberculosis Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Disease Type
        • 7.3.3.2.2. By Therapy
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By Dosage Form
        • 7.3.3.2.5. By Distribution Channel
    • 7.3.4. Italy Tuberculosis Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Disease Type
        • 7.3.4.2.2. By Therapy
        • 7.3.4.2.3. By Route of Administration
        • 7.3.4.2.4. By Dosage Form
        • 7.3.4.2.5. By Distribution Channel
    • 7.3.5. Spain Tuberculosis Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Disease Type
        • 7.3.5.2.2. By Therapy
        • 7.3.5.2.3. By Route of Administration
        • 7.3.5.2.4. By Dosage Form
        • 7.3.5.2.5. By Distribution Channel

8. Asia-Pacific Tuberculosis Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Type
    • 8.2.2. By Therapy
    • 8.2.3. By Route of Administration
    • 8.2.4. By Dosage Form
    • 8.2.5. By Distribution Channel
    • 8.2.6. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Tuberculosis Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Type
        • 8.3.1.2.2. By Therapy
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By Dosage Form
        • 8.3.1.2.5. By Distribution Channel
    • 8.3.2. India Tuberculosis Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Type
        • 8.3.2.2.2. By Therapy
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By Dosage Form
        • 8.3.2.2.5. By Distribution Channel
    • 8.3.3. Japan Tuberculosis Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Type
        • 8.3.3.2.2. By Therapy
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By Dosage Form
        • 8.3.3.2.5. By Distribution Channel
    • 8.3.4. South Korea Tuberculosis Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Disease Type
        • 8.3.4.2.2. By Therapy
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By Dosage Form
        • 8.3.4.2.5. By Distribution Channel
    • 8.3.5. Australia Tuberculosis Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Disease Type
        • 8.3.5.2.2. By Therapy
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By Dosage Form
        • 8.3.5.2.5. By Distribution Channel

9. South America Tuberculosis Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Type
    • 9.2.2. By Therapy
    • 9.2.3. By Route of Administration
    • 9.2.4. By Dosage Form
    • 9.2.5. By Distribution Channel
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Tuberculosis Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Type
        • 9.3.1.2.2. By Therapy
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Dosage Form
        • 9.3.1.2.5. By Distribution Channel
    • 9.3.2. Argentina Tuberculosis Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Type
        • 9.3.2.2.2. By Therapy
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Dosage Form
        • 9.3.2.2.5. By Distribution Channel
    • 9.3.3. Colombia Tuberculosis Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Type
        • 9.3.3.2.2. By Therapy
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Dosage Form
        • 9.3.3.2.5. By Distribution Channel

10. Middle East and Africa Tuberculosis Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease Type
    • 10.2.2. By Therapy
    • 10.2.3. By Route of Administration
    • 10.2.4. By Dosage Form
    • 10.2.5. By Distribution Channel
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Tuberculosis Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease Type
        • 10.3.1.2.2. By Therapy
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By Dosage Form
        • 10.3.1.2.5. By Distribution Channel
    • 10.3.2. Saudi Arabia Tuberculosis Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease Type
        • 10.3.2.2.2. By Therapy
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By Dosage Form
        • 10.3.2.2.5. By Distribution Channel
    • 10.3.3. UAE Tuberculosis Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease Type
        • 10.3.3.2.2. By Therapy
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By Dosage Form
        • 10.3.3.2.5. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global Tuberculosis Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Service Offerings
  • 15.3. Recent Developments
  • 15.4. Key Personnel
  • 15.5. SWOT Analysis
    • 15.5.1. AstraZeneca
    • 15.5.2. Johnson & Johnson
    • 15.5.3. Eli Lilly And Company
    • 15.5.4. Mylan N.V.
    • 15.5.5. Teva Pharmaceutical Industries Ltd.
    • 15.5.6. Sanofi SA
    • 15.5.7. Novartis AG
    • 15.5.8. Sun Pharmaceutical Industries Ltd.
    • 15.5.9. Pfizer Inc.

16. Strategic Recommendations